Pharmaceutical

Novo Nordisk’s ocedurenone Phase III flop costs company $816m

NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.

Jun 28, 2024 - 04:00
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.
Read the original article

Tags:

Previous Article

US CDC recommends routine RSV vaccination for older adults

Next Article

FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Long Covid is a new name for an old syndrome

Opinion: Long Covid is a new name for an old syndrome

Sep 14, 2023

Opinion: How to separate sound wellness solutions from seductive snake oil

Opinion: How to separate sound wellness solutions from ...

Jun 20, 2023

Grit Biotechnology secures funds for development of pipeline programmes

Grit Biotechnology secures funds for development of pip...

Sep 11, 2023